D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Dizal Jiangsu Pharmaceutical Co Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Interest Income Expense
ÂĄ17.1m
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Interest Income Expense
-ÂĄ59.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Interest Income Expense
ÂĄ217.7m
CAGR 3-Years
N/A
CAGR 5-Years
134%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Interest Income Expense
-ÂĄ8.1m
CAGR 3-Years
N/A
CAGR 5-Years
58%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Interest Income Expense
-ÂĄ45.8m
CAGR 3-Years
27%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Interest Income Expense
ÂĄ78.6m
CAGR 3-Years
37%
CAGR 5-Years
99%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Interest Income Expense?
Interest Income Expense
17.1m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Interest Income Expense amounts to 17.1m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
3%

Over the last year, the Interest Income Expense growth was -66%.

Back to Top